Results 31 to 40 of about 188,616 (304)

Renal neuroendocrine tumors

Indian Journal of Urology, 2009
Neuroendocrine tumors (NETs) are uncommon tumors that exhibit a wide range of neuroendocrine differentiation and biological behavior. Primary NETs of the kidney, including carcinoid tumor, small cell carcinoma (SCC), and large cell neuroendocrine carcinoma (LCNEC) are exceedingly rare.The clinicopathologic features of renal NETs diagnosed at a single ...
Brian R Lane, George Jour, Ming Zhou
openaire   +3 more sources

Molecular pathogenesis and targeted therapy of sporadic pancreatic neuroendocrine tumors [PDF]

, 2015
Over the past few years, knowledge regarding the molecular pathology of sporadic pancreatic neuroendocrine tumors (PNETs) has increased substantially, and a number of targeted agents have been tested in clinical trials in this tumor type.
Ahn, Balogh, Bergers, Berruti, Capurso, Capurso, Carew, Castellano, Chamberlain, Chan, Chan, Chen, Clynes, Corbo, Corbo, Couvelard, De Wilde, Di Florio, Di Florio, Di Florio, Fazio, Fendrich, Gaur, Gurung, Han, Heaphy, Heaphy, Hobday, Hopfner, House, Jacinto, Jensen, Jiao, Karnik, Karnik, Komori, Kulke, Laplante, Loewith, Lovejoy, Luzi, Marinoni, Marion-Audibert, Mendel, Meric-Bernstam, Missiaglia, Mocellin, Panzuto, Papouchado, Passacantilli, Perren, Pàez-Ribes, Raymond, Sarbassov, Scoazec, Shah, Shi, Tang, Vinagre, Wang, Yang, Yao, Yuan, Zhang, Zhang   +64 more
core   +1 more source

Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Clinical Diabetes and Endocrinology, 2018
Background Neuroendocrine tumors (NETs) are rare neoplasms, with an estimated annual incidence of ~ 6.9/100,000. NETs arise throughout the body from cells of the diffuse endocrine system.
Inbal Uri, Simona Grozinsky-Glasberg
doaj   +1 more source

Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management

EJNMMI Physics, 2020
Background After each cycle of [177Lu]-DOTA-TATE peptide receptor radionuclide therapy (PRRT) dosimetry is performed to enable precise calculation of the radiation-absorbed dose to tumors and normal organs.
Alexandre Chicheportiche, Simona Ben-Haim, Simona Grozinsky-Glasberg, Kira Oleinikov, Amichay Meirovitz, David J. Gross, Jeremy Godefroy   +6 more
doaj   +1 more source

Pancreatic tumors imaging: an update [PDF]

, 2016
Currently, ultrasound (US), computed tomography (CT) and Magnetic Resonance imaging (MRI) represent the mainstay in the evaluation of pancreatic solid and cystic tumors affecting pancreas in 80-85% and 10-15% of the cases respectively. Integration of US,
Baccari, Paolo, Cappabianca, Salvatore, D'Andrea, Alfredo, Falcone, Giuseppe, Gravante, Sabrina, Manganaro, Lucia, Palumbo, Barbara, Reginelli, Alfonso, Scialpi, Michele   +8 more
core   +1 more source

Cowden Syndrome and Concomitant Pulmonary Neuroendocrine Tumor: A Presentation of Two Cases

Case Reports in Medicine, 2015
Cowden Syndrome is a rare autosomal dominantly inherited disorder. Patients with Cowden Syndrome are at increased risk of various benign and malignant neoplasms in breast, endometrium, thyroid, gastrointestinal tract, and genitourinary system ...
Seppo W. Langer, Lene Ringholm, Christine I. Dali, Rene Horsleben Petersen, Åse Krogh Rasmussen, Anne-Marie Gerdes, Birgitte Federspiel, Ulrich Peter Knigge   +7 more
doaj   +1 more source

Treatment challenges in and outside a specialist network setting: Pancreatic neuroendocrine tumours [PDF]

, 2019
Pancreatic Neuroendocrine Neoplasms comprise a group of rare tumours with special biology, an often indolent behaviour and particular diagnostic and therapeutic requirements.
Almar E., Arveux P., Autelitano M., Baldi I., Bara S., Barchielli A., Benfatto L., Benhamou E., Bento M. J., Bielska-Lasota M., Blaszczyk J., Bordoni A., Botta L., Bouchardy C., Bouvier A. -M., Bouvier V., Brewster D. H., Calleja N., Candela P., Caplin M., Capocaccia R., Carulla M., Clough-Gorr K., Colonna M., Comber H., De Angelis R., de Lacerda G. F., de Munain A. L., Diaz Garcia J. M., Diba C. S., Dimitrova N., Dusek L., Engel J., Ess S. M., Falcini F., Falconi M., Ferretti S., Filiberti R. A., Fusai G. K., Fusco M., Galceran J., Gatta G., Gavin A., Gennaro V., Gentilini M., Giacomin A., Gozdz S., Grosclaude P., Guizard A. -V., Hackl M., Heidrich J., Henau K., Holleczek B., Huws D. W., Iannelli A., Johannesen T. B., Jonasson J. G., Kepska K., Knijn A., Konzelmann I., Kunkler I., Lapotre-Ledoux B., Larranaga N., Leinonen M., Luttmann S., Lykoudis P. M., Madeddu A., Magi M., Malila N., Mallone S., Mangone L., Marani E., Marcos-Gragera R., Maspero S., Maynadie M., Mazzoleni G., Michiara M., Miranda A., Molinie F., Monnereau A., Moreno-Iribas C., Mousavi M., Muffatti F., Navarro C., Nennecke A., Pannozzo F., Partelli S., Pierannunzio D., Piffer S., Pildava S., Primic-Zakelj M., Rachtan J., Rashbass J., Ricci P., Robaszkiewicz M., Rossi S., Rugge M., Salmeron D., Sanchez M. J., Santaquilani M., Sardo A. S., Schubert-Fritschle G., Schvartz C., Sekerija M., Sensi F., Serraino D., Smailyte G., Spagnoli G., Stabenow R., Stracci F., Tagliabue G., Tavilla A., Torrella-Ramos A., Trama A., Tretarre B., Troussard X., Tumino R., Usala M., Van Eycken E., Velten M., Visser O., Vitale F., Woronoff A. -S., Ziino A.   +123 more
core   +1 more source

Expression of a neuroendocrine gene signature in gastric tumor cells from CEA 424-SV40 large T antigen-transgenic mice depends on SV40 large T antigen. [PDF]

PLoS ONE, 2012
BackgroundA large fraction of murine tumors induced by transgenic expression of SV40 large T antigen (SV40 TAg) exhibits a neuroendocrine phenotype. It is unclear whether SV40 TAg induces the neuroendocrine phenotype by preferential transformation of ...
Fritz Ihler, Elena Viviana Vetter, Jie Pan, Robert Kammerer, Svenja Debey-Pascher, Joachim L Schultze, Wolfgang Zimmermann, Georg Enders   +7 more
doaj   +1 more source

Natural History and Management of Familial Paraganglioma Syndrome Type 1: Long-Term Data from a Large Family [PDF]

, 2020
Head and neck paragangliomas are the most common clinical features of familial paraganglioma syndrome type 1 caused by succinate dehydrogenase complex subunit D (SDHD) mutation. The clinical management of this syndrome is still unclear.
Cantisani, Vito, Colao, Annamaria, Di Leo, Nicola, Faggiano, Antongiulio, Feola, Tiziana, Giannetta, Elisa, Isidori, Andrea M, Lenzi, Andrea, Modica, Roberta, Polti, Giorgia, Puliani, Giulia, Sesti, Franz, Verrico, Monica   +12 more
core   +1 more source

Hitherto unseen survival in an ALK‐positive‐patient with advanced stage adult ganglioneuroblastoma treated with personalized medicine

Clinical Case Reports, 2017
Key Clinical Message Survival of stage 4 ganglioneuroblastoma (GNB) patients is poor; no reports exist of patients surviving up to 5 years (1, 2). We report the clinical and therapeutic course of a patient with stage 4 GNB surviving beyond expectations ...
Signe Risum, Ulrich Knigge, Seppo W. Langer   +2 more
doaj   +1 more source